Latest news with #BharatBiotechInternationalLtd
The Hindu
4 days ago
- Science
- The Hindu
Knowledge key to the future, says Bharat Biotech Executive Chairman Krishna M. Ella
The future will be divided between those who possess knowledge and those who do not have it, Krishna M. Ella, founder and Executive Chairman of Bharat Biotech International Ltd, has said. Dr. Ella was speaking at the 13th convocation of the Indian Institute of Science Education and Research Thiruvananthapuram (IISER Thiruvananthapuram) on Saturday. Dr. Ella observed how technologies such as artificial intelligence, quantum science, electric vehicles, solar power and renewable energy and the hydrogen economy were transforming the world. He expressed his belief that thorium, sourced from the coastal sands of Kerala and other locations, would be the future of nuclear energy. He told the new graduates that they were graduating at a time when the technological front was poised for major revolutions in the coming five to 10 years. 'Embrace cutting-edge tech' Arvind Anant Natu, Chairperson, Board of Governors of IISER Thiruvananthapuram, encouraged the graduates to embrace cutting-edge technologies such as artificial intelligence, machine learning, deep learning, and the Internet of Things, as powerful tools in their scientific and entrepreneurial journey. Calling for a holistic and socially responsible approach, he emphasised the importance of addressing societal problems through interdisciplinary thinking. J.N. Moorthy, Director, IISER Thiruvananthapuram, presented a report on the institute's activities. Degrees were conferred on 258 BS-MS, 76 MSc, 15 MS (Research), 26 PhD, and 15 Integrated PhD graduates at the 13th convocation. Medals The Institute Gold Medal for all-round excellence was conferred on Jacob Cherry Sam. The Director's Gold Medal for Academic Excellence' was awarded to Eswar Krishnan N.A., and the Cultural Medal was presented to Adithya J. for contributions to campus cultural life.
Time of India
26-06-2025
- Business
- Time of India
GSK, Bharat Biotech to slash malaria vaccine prices to under $5 per dose by 2028
Representative Image HYDERABAD: Vaccine maker Bharat Biotech International Ltd and British biopharma giant GSK plc will be slashing the prices of the world's first malaria vaccine - RTS,S or Mosquirix - by over half to less than $5 per dose by 2028 as part of their pledges to Gavi's replenishment process for 2026-2030. The proposed price reduction will be driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins, they said in a joint statement on Wednesday.
Mint
08-06-2025
- Health
- Mint
Covaxin maker Bharat Biotech's nasal vaccine ready to take on new covid strains
New Delhi: Bharat Biotech International Ltd, which developed the covaxin vaccine to protect against earlier variants of covid-19, says its intranasal and injectable vaccine platforms are ready to be adapted for new strains of the disease. India has recorded 5,755 active covid cases, according to the Union health ministry's data issued on Sunday. The nation also reported four new fatalities in the last 24 hours, taking the total covid death toll since 1 January to 59. Health officials have identified two new JN.1 covid variants as the cause of the fresh wave of the infectious disease. Suchrita Ella, managing director of Bharat Biotech, said the company's nasal vaccine iNCOVACC is 'specifically designed for flexibility to adapt to circulating strains, protection in upper respiratory tract, and easy administration without injections". 'Bharat Biotech's covid-19 vaccine platforms, both the injectable and intranasal versions, are enabled for adaptation. However, any decision to restart production is contingent upon regulatory agency approvals," she said in an email interview. 'We continue to work in close coordination with regulatory bodies to ensure preparedness always aligns with evolving scientific and safety standards," Ella said, adding that the company is monitoring the situation and is "well positioned to respond effectively". Also read | Covid cases are rising again. Should we be worried? Bharat Biotech and Serum Institute of India manufactured billions of doses of vaccines for Indians and for supplying to more than 100 countries during the first few waves of the covid pandemic. The last covid vaccine batches were manufactured a year ago, with no visibility on new stocks. Dr. Soumya Swaminathan, a former chief scientist at the World Health Organization (WHO), recently emphasized the need for vaccine manufacturers to update their formulas based on new variants, warning that vaccines developed for the original covid strain would offer little protection now. Bharat Biotech halted production of covaxin due to a decline in demand in early 2022 and destroyed significant quantities of its vaccine stock. 'Subsequently, we proceeded with the destruction of about 200 million doses of bulk and about 50 million doses of vaccines in vials," Ella said. Asked if booster doses should be given to high-risk populations, Ella said that remained subject to national regulatory approval. Also read | India steps up surveillance as covid-19 cases surge in Hong Kong and Singapore India's covid preparedness The Union health ministry, while stating that most current covid cases are mild, has directed states and union territories to increase testing and ensure medical preparedness across health facilities, reviewing the availability of oxygen, isolation beds, ventilators, and essential medicines. A nationwide mock drill was conducted last week to assess the functionality of oxygen supply systems in hospitals. The Union government has also advised the public to practise covid-appropriate behaviour, especially avoiding crowded places when unwell and seeking medical intervention. State and district surveillance units are also closely monitoring cases of influenza-like illness (ILL) and severe acute respiratory illness (SARI). As per government guidelines, all admitted SARI patients and 5% of ILI cases are to be tested for covid. Scientists at the Indian Council of Medical Research (ICMR) are conducting genome sequencing of positive samples to track the variants. The latest covid wave is attributed to two new coronavirus variants—NB.1.8.1 and LF.7, which are mutations of the Omicron offspring JN.1 variant. Kerala has reported the maximum number of covid cases this year, at 1,373, followed by Maharashtra (510), Delhi (457), Gujarat (461), and West Bengal (431). According to the Union health ministry, 760 people have recovered from covid in the last 24 hours, bringing the total number of recoveries this year to 5,484. Also read | The official 'data fog' on India's covid toll has finally cleared up. Here's what we know now.
The Print
21-05-2025
- Health
- The Print
Bharat Biotech's cholera vaccine successfully completes Phase-III trials
Ogawa and Inaba are two serotypes of Vibrio cholerae O1, a bacterial species that causes cholera. The vaccine maker, in a press release, said it has demonstrated against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and children, supporting its potential as an effective OCV. Hyderabad, May 21 (PTI) Bharat Biotech International Ltd on Wednesday said its oral Cholera Vaccine Hillchol has successfully completed phase III clinical trials. The findings of a double-blind, randomized phase III clinical trial evaluating the safety, immunogenicity, non-inferiority, and lot-to-lot consistency of the Hillchol oral cholera vaccine, compared to a comparator vaccine, were recently published in a journal. The study involved 1,800 participants, ranging from infants to adults, across 10 clinical sites in India, the release said. The participants were divided into three age groups: adults over 18 years, children aged 5 to under 18 years, and infants aged 1 to under 5 years. They were randomized in a 3:1 ratio to receive either Hillchol or a comparator vaccine. 'This publication reaffirms our commitment to advancing vaccines built on rigorous research, thorough clinical trials, and reliable clinical data. It highlights our continued commitment to providing affordable, effective, and accessible vaccines for the populations who need them the most,' said Krishna Ella, Executive Chairman of Bharat Biotech. Cholera is an acute diarrhoeal infection caused by ingesting food or water contaminated with Vibrio cholerae bacteria. Studies have estimated that 2.86 million cases and 95,000 deaths occur annually, the release further said. Global demand for OCVs is close to 100 million doses a year, and given that only one manufacturer supplies them, there is a global shortage. Bharat Biotech's facilities in Hyderabad and Bhubaneswar have a capacity to produce up to 200 million doses of Hillchol, it added. PTI GDK ADB This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
&w=3840&q=100)
Business Standard
21-05-2025
- Health
- Business Standard
Bharat Biotech's cholera vaccine 'Hillchol' clears phase-III trials
Bharat Biotech International Ltd on Wednesday said its oral Cholera Vaccine Hillchol has successfully completed phase III clinical trials. The vaccine maker, in a press release, said it has demonstrated against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and children, supporting its potential as an effective OCV. Ogawa and Inaba are two serotypes of Vibrio cholerae O1, a bacterial species that causes cholera. The findings of a double-blind, randomized phase III clinical trial evaluating the safety, immunogenicity, non-inferiority, and lot-to-lot consistency of the Hillchol oral cholera vaccine, compared to a comparator vaccine, were recently published in a journal. The study involved 1,800 participants, ranging from infants to adults, across 10 clinical sites in India, the release said. The participants were divided into three age groups: adults over 18 years, children aged 5 to under 18 years, and infants aged 1 to under 5 years. They were randomized in a 3:1 ratio to receive either Hillchol or a comparator vaccine. This publication reaffirms our commitment to advancing vaccines built on rigorous research, thorough clinical trials, and reliable clinical data. It highlights our continued commitment to providing affordable, effective, and accessible vaccines for the populations who need them the most, said Krishna Ella, Executive Chairman of Bharat Biotech. Cholera is an acute diarrhoeal infection caused by ingesting food or water contaminated with Vibrio cholerae bacteria. Studies have estimated that 2.86 million cases and 95,000 deaths occur annually, the release further said. Global demand for OCVs is close to 100 million doses a year, and given that only one manufacturer supplies them, there is a global shortage. Bharat Biotech's facilities in Hyderabad and Bhubaneswar have a capacity to produce up to 200 million doses of Hillchol, it added.
